Global Vectra (GLOBALVECT)
CyclicalScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹150.53 |
| Market Cap | ₹210.74 Cr |
| P/E Ratio | 0 |
| ROCE | 6.66% |
| ROE | -116.17% |
| Dividend Yield | 0% |
| Profit Growth | -270.33% |
| Debt/Equity | 140.97 |
| Sales Growth | 1.1% |
| Promoter Holding | 75% |
| 52-Week Range | ₹129 — ₹248 |
| Sector | Transport Services |
| Book Value | ₹-5.79 |
Strengths
- Positive ROCE of 6.66% suggests some operating-level profitability before debt costs
- Promoter holding at 75% indicates strong insider ownership and alignment
- Latest quarter sales of ₹147 Cr show meaningful revenue scale despite losses
- Sales growth of 3.05% is modest but positive in a difficult airline environment
- Stock trades above its 52-week low of ₹129, showing some market interest
Concerns
- Return on equity is -116.17%, indicating severe shareholder value destruction
- Debt-to-equity of 140.97 is dangerously high for an airline with net losses
- Price-to-book of 22.29 with book value of just ₹8.48 implies an extremely stretched valuation
- Profit growth of -270.33% and a latest quarterly net loss of ₹11 Cr show no earnings stability
AI Analysis
When I look at Global Vectra, I see a business that fails the tests Graham and I would apply. Airlines are tough, capital-hungry, commodity-like businesses, and this one shows all the scars. The latest quarter had sales of ₹147 Cr but a net loss of ₹11 Cr. Return on equity is deeply negative at -116.17%, meaning shareholder capital is being destroyed, not compounded. Book value is just ₹8.48 per share, yet the stock trades at ₹189, a P/B of 22.29. That is an extraordinarily rich price for a company with a shrunken equity base. Debt to equity at 140.97 is alarming; leverage is doing the opposite of what leverage should do. There is a positive ROCE of 6.66%, which suggests operations can earn something before interest costs, but those debt costs overwhelm the profit line. Sales growth is only 3.05% while profit growth is -270.33%; that is no pricing power. Piotroski score of 4/9 reinforces a weak financial position. Dividend yield is zero, so there is no return to patient owners. Promoter holding of 75% at least shows alignment, but it does not offset the balance sheet risk. At ₹189, with no meaningful P/E and negative net profit, I see no margin of safety. This is a cyclical business in a difficult phase. I would prefer to wait until earnings turn positive and debt is reduced before even considering it. Price is what you pay; value is what you get. Here the value is not visible to me.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer